Total Payments
$2.5M
2024 Payments
$147,199
Companies
51
Transactions
2,785
Medicare Patients
2,762
Medicare Billing
$3.6M
Payment Breakdown by Category
Other$1.1M (43.1%)
Royalty/License$1.0M (40.0%)
Consulting$225,650 (9.0%)
Travel$131,203 (5.2%)
Food & Beverage$53,998 (2.2%)
Research$11,912 (0.5%)
Education$381.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $1.0M | 1 | 40.0% |
| Honoraria | $693,473 | 275 | 27.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $382,759 | 213 | 15.3% |
| Consulting Fee | $225,650 | 75 | 9.0% |
| Travel and Lodging | $131,203 | 465 | 5.2% |
| Food and Beverage | $53,998 | 1,738 | 2.2% |
| Unspecified | $11,912 | 5 | 0.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $757.50 | 1 | 0.0% |
| Education | $381.40 | 12 | 0.0% |
Payments by Type
General
$2.5M
2,780 transactions
Research
$11,912
4 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $1.7M | 662 | $0 (2023) |
| Lilly USA, LLC | $322,242 | 524 | $0 (2024) |
| Horizon Pharma plc | $124,676 | 143 | $0 (2018) |
| Amgen Inc. | $89,787 | 201 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $60,585 | 179 | $0 (2024) |
| ABBVIE INC. | $38,124 | 209 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $25,556 | 46 | $0 (2019) |
| UCB, Inc. | $23,287 | 70 | $0 (2024) |
| Janssen Biotech, Inc. | $20,585 | 173 | $0 (2024) |
| United Rheumatology | $17,500 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $147,199 | 268 | Amgen Inc. ($85,370) |
| 2023 | $203,950 | 319 | Horizon Therapeutics plc ($156,710) |
| 2022 | $1.2M | 327 | Horizon Therapeutics plc ($1.1M) |
| 2021 | $205,565 | 313 | Horizon Therapeutics plc ($161,205) |
| 2020 | $162,948 | 290 | Horizon Therapeutics plc ($85,706) |
| 2019 | $295,180 | 515 | Horizon Therapeutics plc ($188,955) |
| 2018 | $192,963 | 465 | Horizon Pharma plc ($74,384) |
| 2017 | $114,485 | 288 | Horizon Pharma plc ($50,292) |
All Payment Transactions
2,785 individual payment records from CMS Open Payments — Page 1 of 112
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $30.60 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.81 | General |
| Category: Immunology | ||||||
| 12/14/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,430.00 | General |
| Category: Immunology | ||||||
| 12/13/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $26.94 | General |
| Category: Rare Disease | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.40 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | ILARIS (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: Immunology | ||||||
| 12/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $11.89 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $11.67 | General |
| 12/05/2024 | SOBI, INC | KINERET (Drug) | Food and Beverage | In-kind items and services | $7.22 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $80.14 | General |
| 12/04/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $25.67 | General |
| Category: Dermatology | ||||||
| 12/03/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $111.00 | General |
| Category: Immunology | ||||||
| 12/03/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $33.50 | General |
| Category: Immunology | ||||||
| 11/27/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $29.45 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $14.68 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $31.13 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $19.53 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $45.12 | General |
| 11/20/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $6,440.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $920.00 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $62.18 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/14/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $8.57 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS | Eli Lilly and Company | $7,359 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | Eli Lilly and Company | $2,040 | 1 |
| A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | Eli Lilly and Company | $1,308 | 1 |
| A PHASE 3 MULTICENTER STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | Eli Lilly and Company | $1,205 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 825 | 49,401 | $4.0M | $1.0M |
| 2022 | 18 | 822 | 42,330 | $3.5M | $977,685 |
| 2021 | 17 | 529 | 28,350 | $2.5M | $806,692 |
| 2020 | 17 | 586 | 25,325 | $2.3M | $817,216 |
Total Patients
2,762
Total Services
145,406
Medicare Billing
$3.6M
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 15 | 11,725 | $1.1M | $395,313 | 35.8% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 31 | 26,352 | $1.3M | $277,899 | 21.3% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 29 | 5,690 | $962,300 | $144,831 | 15.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 36 | 3,480 | $124,560 | $64,124 | 51.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 91 | 509 | $205,004 | $50,840 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 246 | 522 | $184,032 | $47,077 | 25.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 57 | 76 | $35,068 | $9,948 | 28.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 46 | 46 | $27,029 | $5,870 | 21.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 32 | 32 | $24,311 | $5,535 | 22.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 37 | 167 | $13,636 | $3,694 | 27.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 35 | $8,530 | $2,105 | 24.7% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 15 | 46 | $6,518 | $2,051 | 31.5% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 15 | 32 | $6,694 | $1,723 | 25.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 42 | 70 | $3,925 | $732.75 | 18.7% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 87 | 499 | $3,215 | $249.95 | 7.8% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 21 | 120 | $1,200 | $90.61 | 7.6% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 17 | 12,976 | $1.2M | $449,760 | 36.8% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 27 | 20,086 | $1.0M | $234,487 | 23.4% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 23 | 4,610 | $783,700 | $131,625 | 16.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 272 | 625 | $161,340 | $53,778 | 33.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 31 | 2,520 | $88,200 | $42,657 | 48.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 73 | 258 | $96,132 | $28,173 | 29.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 46 | 188 | $33,692 | $9,402 | 27.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 44 | 44 | $31,692 | $7,883 | 24.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 33 | 45 | $19,015 | $6,059 | 31.9% |
About Dr. Jeff Peterson, MD
Dr. Jeff Peterson, MD is a Rheumatology healthcare provider based in Bothell, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467491076.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeff Peterson, MD has received a total of $2.5M in payments from pharmaceutical and medical device companies, with $147,199 received in 2024. These payments were reported across 2,785 transactions from 51 companies. The most common payment nature is "Royalty or License" ($1.0M).
As a Medicare-enrolled provider, Peterson has provided services to 2,762 Medicare beneficiaries, totaling 145,406 services with total Medicare billing of $3.6M. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Bothell, WA
- Active Since 06/06/2006
- Last Updated 06/12/2023
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1467491076
Products in Payments
- KRYSTEXXA (Biological) $1.8M
- TALTZ (Drug) $214,104
- KRYSTEXXA (Drug) $124,069
- COSENTYX (Biological) $51,983
- OLUMIANT (Drug) $26,660
- ACTHAR (Biological) $25,616
- Humira (Biological) $15,745
- BENLYSTA (Biological) $13,336
- TREMFYA (Drug) $10,712
- SIMPONI ARIA (Biological) $9,946
- Bimzelx (Biological) $9,095
- KEVZARA SARILUMAB INJECTION (Biological) $7,885
- Cimzia (Drug) $6,162
- NO PRODUCT DISCUSSED (Drug) $5,953
- RINVOQ (Biological) $5,205
- KEVZARA (Biological) $3,938
- KEVZARA (Drug) $3,436
- Otezla (Drug) $3,192
- COSENTYX (Drug) $2,574
- Enbrel (Biological) $1,651
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.